Prostate Cancer

Bone-protecting agents utilized during treatment with radium-223 plus enzalutamide reduced the risk for fractures in men with asymptomatic or mildly symptomatic metastatic castration-resistant prostate cancer.

The tri-specific half-life extended prostate-specific membrane antigen-targeting T cell engager HPN424 demonstrated antitumor activity and was well tolerated in patients with metastatic castration-resistant prostate cancer.

Darolutamide remained well tolerated with a highly favorable safety profile when combined with androgen deprivation therapy in the treatment of patients with nonmetastatic castration-resistant prostate cancer.

177Lu-PSMA-617, a targeted radioligand therapy, plus standard of care induced approximately a 40% reduction in the risk of death vs SOC alone in men with progressive PSMA-positive metastatic castration-resistant prostate cancer.

Jason Zhu, MD, discusses treatment strategies for patients with node-positive prostate cancer.

Earle Burgess, MD, discusses the need for improved biomarkers for PARP inhibitors in prostate cancer.

Anita Johnson, MD, FACS, discusses existing disparities in cancer, studies that have helped to shed further light on the issue, and ongoing efforts being made to improve outcomes in all patients.

The combination of cabozantinib plus atezolizumab was found to elicit encouraging response rates, disease control, and acceptable safety in patients with metastatic castration-resistant prostate cancer who had previously received enzalutamide and/or abiraterone acetate.

The FDA has approved a 6-month subcutaneous depot formulation of leuprolide mesylate as a ready-to-use treatment for patients with advanced prostate cancer.

The FDA has approved piflufolastat F 18 injection, a prostate-specific membrane antigen–targeted positron emission tomography imaging agent to identify suspected metastasis or recurrence of prostate cancer.

Álvaro Juárez Soto, MD, discusses the rationale to analyze the Latin American subgroup of patients with metastatic hormone-sensitive prostate cancer evaluated in the phase 3 TITAN trial.

Natasha Garg, DO, discusses selecting between antiandrogen agents in nonmetastatic castration-resistant prostate cancer.

Eric M. Horwitz, MD, FABS, FASTRO, and Stephanie E. Weiss, MD, FASTRO, highlight ongoing research efforts with radiation therapy that are generating excitement at their institution.

Stephanie E. Weiss, MD, FASTRO and Eric M. Horwitz, MD, FABS, FASTRO, discuss ways to leverage radiation in the treatment of central nervous system metastases, areas of active investigation, and different available strategies that are improving outcomes for patients with cancer.

Earle Burgess, MD, discusses future directions with PARP inhibitors in prostate cancer.

Stereotactic body radiotherapy can safely be used to treat patients with oligometastatic disease with 3 to 4 metastases or 2 metastases in close proximity to each other, according to results from the phase 1 NRG-BR001 trial.

Prophylactic whole-pelvic radiotherapy improved biochemical failure-free survival and disease-free survival vs prostate-only radiotherapy in patients with high-risk, locally advanced prostate cancer.

An increase in the frequency of prostate-specific antigen (PSA) screening was associated with a nearly 25% reduction in prostate cancer–specific mortality in younger African Americans, according to data from a study presented in a presscast held ahead of the 2021 ASCO Annual Meeting.

Anita Johnson, MD, FACS, discusses racial disparities in outcomes across multiple tumor types.

Matthew C. Ward, MD, discusses when to consider adding systemic therapy to radiation therapy in prostate cancer.

Eric M. Horwitz, MD, FABS, FASTRO, discusses the evolution of radiation therapy in prostate cancer.

Leonard G. Gomella, MD, discusses using novel biomarkers to inform whether a biopsy is needed in prostate cancer.

The use of 18F-fluciclovine-PET/CT in guiding salvage treatment with radiotherapy after prostatectomy reduced the likelihood of biochemical recurrence or suboptimal response to treatment in patients with prostate cancer without evidence of extrapelvic disease with conventional imaging.

Columbia University Irving Medical Center will partner with Advaxis, Inc. to fund a phase 1 clinical trial that seeks to examine the novel off-the-shelf neoantigen immunotherapy agent ADXS-504 in patients with biochemically recurrent prostate cancer.

The FDA has granted a breakthrough device designation to the Avenda Health Focal Therapy System, a male “lumpectomy” product under development to treat patients with prostate cancer in office while preserving quality of life.